Polymorphisms of MAD2L2 rs746218 and TNFRSF1A rs4149570 polymorphisms may be biomarkers for predicting prognosis in patients with lung cancer treated with platinum-based chemotherapy. The gene discussed is MAD2L2; the disease is lung carcinoma.